Thomas Marjot

4.7k total citations · 2 hit papers
49 papers, 1.8k citations indexed

About

Thomas Marjot is a scholar working on Epidemiology, Endocrinology, Diabetes and Metabolism and Infectious Diseases. According to data from OpenAlex, Thomas Marjot has authored 49 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 15 papers in Endocrinology, Diabetes and Metabolism and 11 papers in Infectious Diseases. Recurrent topics in Thomas Marjot's work include Liver Disease Diagnosis and Treatment (22 papers), Diet, Metabolism, and Disease (12 papers) and COVID-19 Clinical Research Studies (9 papers). Thomas Marjot is often cited by papers focused on Liver Disease Diagnosis and Treatment (22 papers), Diet, Metabolism, and Disease (12 papers) and COVID-19 Clinical Research Studies (9 papers). Thomas Marjot collaborates with scholars based in United Kingdom, United States and Germany. Thomas Marjot's co-authors include Jeremy Tomlinson, Jeremy Cobbold, Jonathan Hazlehurst, Conor Woods, Leanne Hodson, Eleanor Barnes, Andrew M. Moon, Ahmad Moolla, A. Sidney Barritt and Gwilym J. Webb and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and PLoS ONE.

In The Last Decade

Thomas Marjot

44 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Non-alcoholic fatty liver disease and diabetes

2016 403 citations Jonathan Hazlehurst, Conor Woods et al. Metabolism profile →
COVID-19 and liver disease: mechanistic and clinical perspectives

2021 251 citations Thomas Marjot, Gwilym J. Webb et al. Nature Reviews Gastroenterology & Hepatology profile →

Peers

Countries citing papers authored by Thomas Marjot

Since Specialization

Citations

This map shows the geographic impact of Thomas Marjot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Marjot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Marjot more than expected).

Fields of papers citing papers by Thomas Marjot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Marjot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Marjot. The network helps show where Thomas Marjot may publish in the future.

Co-authorship network of co-authors of Thomas Marjot

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Marjot. A scholar is included among the top collaborators of Thomas Marjot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Marjot. Thomas Marjot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The barriers to uptake of artificial intelligence in hepatology and how to overcome them 2025 ·Journal of Hepatology ·Jan Clusmann, (unknown), Octavi Bassegoda, Carolin V. Schneider, Tobias Paul Seraphin, (unknown), Tom Luedde, Raquel Pérez-López, Julien Caldéraro, Stephen Gilbert, Thomas Marjot, Ashley Spann, Debbie L. Shawcross, Sabela Lens, Eric Trépo, Jakob Nikolas Kather	3
2	The endothelium as the gatekeeper of insulin’s action on metabolic tissues: Implications for MASLD and MASH 2025 ·Journal of Hepatology ·Thomas Marjot	1
3	Glycated haemoglobin is a major predictor of disease severity in patients with NAFLD 2024 ·Diabetes Research and Clinical Practice ·Santo Colosimo, (unknown), Dimitrios A. Koutoukidis, Thomas Marjot, Garry D. Tan, D. J. Harman, Guruprasad P. Aithal, Pinelopi Manousou, Roberta Forlano, Richard Parker, David Sheridan, Philip N. Newsome, William Alazawi, Jeremy Cobbold, Jeremy Tomlinson	5
4	New evidence of cross-disease communication between heart and liver 2024 ·Journal of Hepatology ·Thomas Marjot	0
5	Is it time for chronopharmacology in NASH? 2022 ·Journal of Hepatology ·Thomas Marjot, David Ray, Jeremy Tomlinson	20
6	Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper 2022 ·Journal of Hepatology ·Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, L Belli, Marina Berenguer, Marı́a Buti, Rajiv Jalan, Mario U. Mondelli, Richard Moreau, Daniel Shouval, Thomas Berg, Markus Cornberg	43
7	SARS-CoV-2 Infection and Liver Disease: A Review of Pathogenesis and Outcomes 2022 ·Gut and Liver ·(unknown), Thomas Marjot, Eleanor Barnes, A. Sidney Barritt, Gwilym J. Webb, Andrew M. Moon	7
8	Acute intermittent hypoxia drives hepatic de novo lipogenesis in humans and rodents 2022 ·SHILAP Revista de lepidopterología ·Jonathan Hazlehurst, (unknown), Catriona Charlton, Jack J. Miller, Laura Gathercole, Thomas Cornfield, Nikolaos Nikolaou, Shelley Harris, Ahmad Moolla, (unknown), Lisa C. Heather, Thomas Marjot, Damian J. Tyler, Carolyn A. Carr, Leanne Hodson, Jane A. McKeating, Jeremy Tomlinson	9
9	COVID-19 and liver disease 2022 ·Gut ·Jean‐François Dufour, Thomas Marjot, Chiara Becchetti, Herbert Tilg	49
10	P048 Geographic variability in rates of intensive care unit admission in patients with chronic liver disease and critical COVID-19: International registry data 2021 ·Thomas Marjot, Andrew M. Moon, Matthew J. Armstrong, Ignacio García‐Juárez, Anand V. Kulkarni, Steven Masson, Nneka N. Ufere, David T. Wong, (unknown), (unknown), A. Sidney Barritt, Eleanor Barnes, Gwilym J. Webb	1
11	Longitudinal Analysis of the Utility of Liver Biochemistry as Prognostic Markers in Hospitalized Patients With Corona Virus Disease 2019 2021 ·Hepatology Communications ·Tingyan Wang, David A. Smith, Cori Campbell, Steve Harris, Hizni Salih, (unknown), Kerrie Woods, (unknown), Oliver Freeman, (unknown), Thomas Marjot, Gwilym J. Webb, Jim Davies, Eleanor Barnes, Philippa C. Matthews	6
12	SARS-CoV-2 infection in patients with autoimmune hepatitis 2021 ·Journal of Hepatology ·Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes, A. Sidney Barritt, Matthew J. Armstrong, (unknown), James Kennedy, Carolyn Mercer, Ann‐Kathrin Ozga, Christian Casar, Christoph Schramm, Andrew M. Moon, Gwilym J. Webb, Ansgar W. Lohse	76
13	OTH-1 SARS-CoV-2 Infection in patients with autoimmune hepatitis 2021 ·Thomas Marjot, Gustav Buescher, Marcial Sebode, Eleanor Barnes, A. Sidney Barritt, Matthew J. Armstrong, (unknown), James C. Kennedy, Carolyn Mercer, Ann‐Kathrin Ozga, Christian Casar, Christoph Schramm, (unknown), Andrew M. Moon, Gwilym J. Webb, Ansgar W. Lohse	1
14	COVID-19 and liver disease: mechanistic and clinical perspectives breakdown → 2021 ·Nature Reviews Gastroenterology & Hepatology ·Thomas Marjot, Gwilym J. Webb, A. Sidney Barritt, Andrew M. Moon, Zania Stamataki, Vincent Wai‐Sun Wong, Eleanor Barnes	251
15	Sleep and liver disease: a bidirectional relationship 2021 ·The Lancet. Gastroenterology & hepatology ·Thomas Marjot, David Ray, Felicity Williams, Jeremy Tomlinson, Matthew J. Armstrong	64
16	SARS-CoV-2 vaccination in patients with liver disease: responding to the next big question 2021 ·The Lancet. Gastroenterology & hepatology ·Thomas Marjot, Gwilym J. Webb, A. Sidney Barritt, Pere Ginès, Ansgar W. Lohse, Andrew M. Moon, Elisa Pose, Palak Trivedi, Eleanor Barnes	39
17	Co-administration of 5α-reductase Inhibitors Worsens the Adverse Metabolic Effects of Prescribed Glucocorticoids 2020 ·The Journal of Clinical Endocrinology & Metabolism ·(unknown), Thomas Marjot, Conor Woods, Jonathan Hazlehurst, Nikolaos Nikolaou, Riccardo Pofi, (unknown), (unknown), Craig Webster, (unknown), Thomas Cornfield, Ahmad Moolla, Andrea M. Isidori, Leanne Hodson, Jeremy Tomlinson	8
18	Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic 2020 ·JHEP Reports ·Tobias Boettler, Thomas Marjot, Philip N. Newsome, Mario U. Mondelli, Mojca Matičič, Elisa Cordero, Rajiv Jalan, Richard Moreau, Markus Cornberg, Thomas Berg	106
19	What is HFE haemochromatosis? 2016 ·British Journal of Hospital Medicine ·Thomas Marjot, Jane Collier, John Ryan	3
20	Non-alcoholic fatty liver disease and diabetes breakdown → 2016 ·Metabolism ·Jonathan Hazlehurst, Conor Woods, Thomas Marjot, Jeremy Cobbold, Jeremy Tomlinson	403

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact